| Drug fever RA Patel, JC Gallagher Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 30 (1 …, 2010 | 201 | 2010 |
| â-lactam/â-lactamase inhibitor combinations: from then to now KA Toussaint, JC Gallagher Annals of Pharmacotherapy 49 (1), 86-98, 2015 | 162 | 2015 |
| Allergic cross-sensitivity between penicillin, carbapenem, and monobactam antibiotics: what are the chances? J Frumin, JC Gallagher Annals of Pharmacotherapy 43 (2), 304-315, 2009 | 130 | 2009 |
| Multicenter study of outcomes with ceftazidime-avibactam in patients with carbapenem-resistant Enterobacteriaceae infections M King, E Heil, S Kuriakose, T Bias, V Huang, C El-Beyrouty, D McCoy, ... Antimicrobial agents and chemotherapy 61 (7), 10.1128/aac. 00449-17, 2017 | 122 | 2017 |
| Antibiotics simplified JC Gallagher, C MacDougall Jones & Bartlett Learning, 2022 | 108 | 2022 |
| Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: A Multicenter Study JC Gallagher, MJ Satlin, A Elabor, N Saraiya, EK McCreary, E Molnar, ... Open forum infectious diseases 5 (11), ofy280, 2018 | 107 | 2018 |
| Shortened courses of antibiotics for bacterial infections: a systematic review of randomized controlled trials AM Hanretty, JC Gallagher Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 38 (6 …, 2018 | 102 | 2018 |
| Knowledge and attitudes of doctor of pharmacy students regarding the appropriate use of antimicrobials JA Justo, TP Gauthier, MH Scheetz, EB Chahine, PB Bookstaver, ... Clinical Infectious Diseases 59 (suppl_3), S162-S169, 2014 | 94 | 2014 |
| Beta-lactam hypersensitivity and cross-reactivity AT Terico, JC Gallagher Journal of pharmacy practice 27 (6), 530-544, 2014 | 76 | 2014 |
| Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infectious diseases specialists … L Papst, B Beović, C Pulcini, E Durante-Mangoni, J Rodríguez-Baño, ... Clinical Microbiology and Infection 24 (10), 1070-1076, 2018 | 73 | 2018 |
| Ertapenem-containing double-carbapenem therapy for treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae JB Cprek, JC Gallagher Antimicrobial agents and chemotherapy 60 (1), 669-673, 2016 | 71 | 2016 |
| Issues in Internet pharmacy practice JC Gallagher, JL Colaizzi Annals of Pharmacotherapy 34 (12), 1483-1485, 2000 | 69 | 2000 |
| The epidemiology, evolution, and treatment of KPC-producing organisms AM Porreca, KV Sullivan, JC Gallagher Current infectious disease reports 20, 1-12, 2018 | 68 | 2018 |
| Vancomycin-resistant enterococcal bacteremia pharmacotherapy R Patel, JC Gallagher Annals of Pharmacotherapy 49 (1), 69-85, 2015 | 66 | 2015 |
| Daptomycin therapy for vancomycin‐resistant enterococcal bacteremia: a retrospective case series of 30 patients JC Gallagher, ME Perez, EA Marino, LG LoCastro, LA Abrardo, ... Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 29 (7 …, 2009 | 66 | 2009 |
| Tigecycline for the treatment of Acinetobacter infections: a case series JC Gallagher, HM Rouse Annals of Pharmacotherapy 42 (9), 1188-1194, 2008 | 61 | 2008 |
| Clinical and economic benefits of fidaxomicin compared to vancomycin for Clostridium difficile infection JC Gallagher, JP Reilly, B Navalkele, G Downham, K Haynes, M Trivedi Antimicrobial agents and chemotherapy 59 (11), 7007-7010, 2015 | 58 | 2015 |
| Antifungal pharmacotherapy for invasive mould infections JC Gallagher, ESD Ashley, RH Drew, JR Perfect Expert Opinion on Pharmacotherapy 4 (2), 147-164, 2003 | 58 | 2003 |
| The essential role of pharmacists in antimicrobial stewardship EL Heil, JL Kuti, DT Bearden, JC Gallagher infection control & hospital epidemiology 37 (7), 753-754, 2016 | 57 | 2016 |
| Infectious diseases Society of America guidelines on the treatment and management of patients with COVID-19. Infectious diseases Society of America 2021; Version 4.2. 0 A Bhimraj, RL Morgan, AH Shumaker, V Lavergne, L Baden, VC Cheng, ... Version 10 (0), 2021 | 52 | 2021 |
